Achaogen (AKAO) Receiving Somewhat Favorable Media Coverage, Analysis Shows
Media coverage about Achaogen (NASDAQ:AKAO) has been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Achaogen earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.3735354438299 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern’s rankings:
- Analysts Expect Achaogen Inc (AKAO) Will Post Earnings of -$0.92 Per Share (americanbankingnews.com)
- Achaogen to host lunch updating investors on commercial strategy post FDA approval of Plazomicin (seekingalpha.com)
- Achaogen: Zemdri To The Rescue (seekingalpha.com)
- Achaogen, Inc. (AKAO): Is this Stock Safe to Play in? (bitcoinpriceupdate.review)
- Shareholders are distrustful How to React (Brief breakdown)- Achaogen, Inc. (NASDAQ:AKAO), Cars.com Inc. (NYSE … (thestreetpoint.com)
AKAO has been the topic of a number of analyst reports. Zacks Investment Research cut shares of Achaogen from a “hold” rating to a “sell” rating in a report on Tuesday, May 1st. BidaskClub upgraded shares of Achaogen from a “hold” rating to a “buy” rating in a research report on Monday, June 18th. HC Wainwright restated a “buy” rating and set a $29.00 price target (up from $19.00) on shares of Achaogen in a research report on Monday, April 30th. Needham & Company LLC restated a “buy” rating and set a $20.00 price target on shares of Achaogen in a research report on Monday, April 30th. Finally, Wedbush reduced their price target on shares of Achaogen from $21.00 to $20.00 and set an “outperform” rating for the company in a research report on Wednesday, June 27th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. Achaogen currently has an average rating of “Hold” and a consensus target price of $20.45.
Achaogen (NASDAQ:AKAO) last released its quarterly earnings results on Friday, May 4th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.17). The firm had revenue of $2.14 million for the quarter, compared to analysts’ expectations of $1.25 million. Achaogen had a negative net margin of 2,384.08% and a negative return on equity of 97.86%. analysts expect that Achaogen will post -3.51 earnings per share for the current year.
In related news, major shareholder Robert W. Duggan bought 119,700 shares of the business’s stock in a transaction that occurred on Thursday, April 19th. The stock was bought at an average cost of $12.76 per share, for a total transaction of $1,527,372.00. Following the completion of the transaction, the insider now owns 6,602,269 shares of the company’s stock, valued at $84,244,952.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Robert W. Duggan bought 976,880 shares of the business’s stock in a transaction that occurred on Thursday, May 3rd. The stock was bought at an average price of $11.33 per share, with a total value of $11,068,050.40. Following the completion of the transaction, the insider now directly owns 8,027,627 shares of the company’s stock, valued at approximately $90,953,013.91. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 1,745,013 shares of company stock valued at $21,050,583 and sold 4,353 shares valued at $46,671. 7.80% of the stock is currently owned by insiders.
Achaogen Company Profile
Achaogen, Inc, a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.